New drug ICP-538 tested in healthy people for first time
NCT ID NCT07535099
First seen Apr 24, 2026 · Last updated Jun 23, 2026 · Updated 8 times
Summary
This early-phase trial is testing the safety and tolerability of a new drug called ICP-538 in 104 healthy adults. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and how the drug moves through the body. The goal is to gather basic safety information, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTH SERVICES RESEARCH are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Gobroad Hospital
RECRUITINGBeijing, Beijing Municipality, 102200, China
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ICP-538
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.